Search

Ivermectin belongs to the group of avermectins, a group of macrocyclic lactones produced by Streptomyces avermitilis, this drug is widely used in the treatment of endoparasitoses and ectoparasitosis in different species of mammals around the world. Based on this need to develop an adequate sanitary management of fish farms and the therapeutic importance of macrocyclic lactones, this study aimed to evaluate the clinical safety of ivermectin administered orally as part of the feed for Nile tilapia (O. niloticus). For this, 56 tilapias (O. niloticus), ±100g, were placed in 7 aquariums (n=8) with a capacity of 100 L of water, supplied with running water devoid of chlorine, with the following treatments being preserved: T0 (Control, untreated), T1 and T2 (treated with 125 and 625µg/kg-1 of ivermectin, respectively). Blood samples were collected for hemogram, leukogram and evaluation of serum biochemical parameters, in addition to organs such as spleen, liver and kidneys (cranial and caudal) for somatic evaluation. The results admired an increase in serum levels of ALT, AST and glycemia, a reduction in cholesterol and triglyceride values at the highest dose, in addition to a decrease in total protein levels and liver somatic analysis. There was no change in hematological parameters, while the leukocyte profile indicated a significant increase in total leukocytes in treated tilapia with lymphocytosis and neutrophilia.. Therefore, treatment with high doses of ivermectin can harm the health of Nile tilapia, requiring additional studies to establish safe therapeutic protocols for these animals. [ABSTRACT FROM AUTHOR]

This study aimed to evaluate the effect of astaxanthin on the hematological, biochemical and somatic response of Nile tilapia (Oreochromis niloticus) orally administered in the feed for a period of 60 days. For the study, 105 tilapia (n=35) from the same spawn were used, constituting the following treatments: Control = animals (not treated with astaxanthin); T100 and T200 = fish treated with 100 and 200 mg of astaxanthin/kg of feed, respectively. There were no hematological alterations in red blood cells counts, hematocrit, hemoglobin, MCV and MCHC. In addition, astaxanthin-fed tilapia presented a better thrombocyte and leukocyte responses with a marked decrease in the number of thrombocytes, lymphocytes and neutrophils. Among treatments, there were no changes in serum levels of total protein, albumin, globulins, aspartate aminotransferase and alkaline phosphate. Treatment with astaxanthin resulted in a decrease in triglyceride and glucose levels, as well as increase in hepatosomatic indices. The results of hematological and biochemical analyzes of tilapias demonstrated the clinical safety of this carotenoid, not causing harmful effects to the health of fish. Therefore, the antioxidant activity of this compound in tilapias resulted in an improvement in the leukocyte profile and contributed to hypolipidemic effects at the dose of 200mg of astaxanthin/kg of feed. [ABSTRACT FROM AUTHOR]